ArticleInternational urogynecology journal2025
The Long-Term Effects of Pessary Treatment on Quality of Life, Symptoms, Sexual Function, and the Urinary System in Women with Pelvic Organ Prolapse.
Article in International urogynecology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "The Long-Term Effects of Pessary Treatment on Quality of Life, Symptoms, Sexual Function, and the Urinary System in Women with Pelvic Organ Prolapse".International urogynecology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisAlthough pessary treatment is widely used to treat pelvic organ prolapse (POP), there is currently no clear information on its impact on long-term quality of life. The aim of this study was to examine the effects of pessary treatment on quality of life (QoL), symptoms, sexual function, and the urinary system in women with POP.
methodsPatients who presented to our clinic due to POP and were treated with a pessary were evaluated. To examine the effects of pessary treatment on QoL, the urinary system, and sexual function, validated questionnaires, including the Pelvic Floor Distress Inventory-20 (PFDI-20), the Pelvic Floor Impact Questionnaire (PFIQ), and the Female Sexual Function Index (FSFI), were completed by those who continued to receive pessary treatment. The patients' gynecological examinations were performed.
resultsSeventy patients were enrolled in the study. Four patients died owing to systemic comorbidities. Among the remaining patients, 12 discontinued pessary use (mean duration 27.36 months), while 54 continued the treatment (mean duration 25.43 months). The pessary size, total vaginal length (TVL), and genital hiatus (GH) of women with POP who discontinued treatment were greater than those who continued treatment. Previous gynecological operations and increased TVL were effective predictors for discontinuation of treatment. The total score and subheadings of the PFDI-20; PFIQ total score and subheadings, with the exception of the Colorectal-Anal Impact Questionnaire (CRAIQ-7); and FSFI scores improved after pessary treatment. Among patients who discontinued treatment, pain was the most common reason (41.6%).
conclusionsPessary treatment was associated with improvements in pelvic floor-related quality of life and sexual function; however, pain emerged as the primary reason for treatment discontinuation.
Indexed as
Identifiers
40856846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.